tirzepatide trials In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide - A New Dawn

Ultrason Sonochem 70:105274

These multifaceted metabolic effects position dual GLP-1/GIP receptor agonists as superior therapeutic candidates for MASLD, especially in patients with coexisting obesity and T2DM, where dysregulated glucose and lipid metabolism drive the progression of the disease

Minimal response after 3+ months often indicates a genetic predisposition to lower GLP1R sensitivity or an underlying medical or lifestyle factor

Journal Of The American College Of Cardiology 2026, 87: 1415-1417

Beyond 28 days, peptide bond hydrolysis and copper oxidation significantly reduce potency even under ideal refrigeration